Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide plus Cisplatin vs High-Dose IFN-a2b in Resected Mucosal Melanoma
NCT03435302Phase 3Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Feb 2014
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of temozolomide, cisplatin in mucosal melanoma (MM), sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
temozolomidecisplatin
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT03435302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03435302.